Immune-related adverse events with immune checkpoint blockade: a comprehensive review
| Autor: | Franck Carbonnel, Vincent Ribrag, Amandine Berdelou, N Amellal, Antoine Hollebecque, Jean-Marie Michot, J.P. Armand, A. Gazzah, Sophie Postel-Vinay, Ratislav Bahleda, Stéphane Champiat, Olivier Lambotte, Jean-Charles Soria, Nicolas Noel, Christophe Massard, Eric Angevin, Andreea Varga, Michael Collins, Christine Mateus, Caroline Robert, Aurélien Marabelle, Celine Boutros, Alina Fuerea, Camille Bigenwald |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Cancer Research Drug-Related Side Effects and Adverse Reactions medicine.medical_treatment Antineoplastic Agents Biology Antibodies B7-H1 Antigen Abatacept 03 medical and health sciences 0302 clinical medicine Immune system Antigen Cancer immunotherapy Risk Factors Neoplasms medicine Animals Humans CTLA-4 Antigen Molecular Targeted Therapy Cancer Immunosuppression Immunotherapy medicine.disease Immune checkpoint Treatment Outcome 030104 developmental biology Oncology 030220 oncology & carcinogenesis Immunology biology.protein Antibody Signal Transduction |
| Zdroj: | European Journal of Cancer. 54:139-148 |
| ISSN: | 0959-8049 |
| Popis: | Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used to target immune cells rather than cancer cells. The first generation of new immunotherapies corresponds to antagonistic antibodies that block specific immune checkpoint molecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein (PD-1) and its ligand PD-L1. Targeting these checkpoints in patients living with cancer had led to long-lasting tumour responses. By unbalancing the immune system, these new immunotherapies also generate dysimmune toxicities, called immune-related adverse events (IRAEs) that mainly involve the gut, skin, endocrine glands, liver, and lung but can potentially affect any tissue. In view of their undisputed clinical efficacy, anti-CTLA-4 and anti-PD-1 antibodies are entering in the routine oncological practice, and the number of patients exposed to these drugs will increase dramatically in the near future. Although steroids can be used to treat these IRAEs, the associated immunosuppression may compromise the antitumour response. Oncologists must be ready to detect and manage these new types of adverse events. This review focuses on the mechanisms of IRAE generation, putative relationship between dysimmune toxicity and antitumour efficacy, as a basis for management guidelines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect